Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP boosted its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 15.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 55,207 shares of the company's stock after buying an additional 7,575 shares during the quarter. ExodusPoint Capital Management LP owned 0.08% of Akero Therapeutics worth $1,536,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in AKRO. SG Americas Securities LLC boosted its stake in shares of Akero Therapeutics by 4,022.1% during the 4th quarter. SG Americas Securities LLC now owns 597,993 shares of the company's stock worth $16,636,000 after acquiring an additional 583,486 shares in the last quarter. Great Lakes Advisors LLC acquired a new stake in Akero Therapeutics in the fourth quarter valued at $5,380,000. abrdn plc increased its position in shares of Akero Therapeutics by 118.7% in the fourth quarter. abrdn plc now owns 269,782 shares of the company's stock valued at $7,505,000 after buying an additional 146,424 shares in the last quarter. Exome Asset Management LLC acquired a new position in shares of Akero Therapeutics during the 3rd quarter worth $2,212,000. Finally, Barclays PLC boosted its position in shares of Akero Therapeutics by 127.9% in the 3rd quarter. Barclays PLC now owns 127,668 shares of the company's stock worth $3,662,000 after buying an additional 71,652 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on AKRO shares. Morgan Stanley restated an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. UBS Group lifted their price objective on Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Citigroup increased their target price on Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. HC Wainwright boosted their price target on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a report on Monday, March 3rd. Finally, Canaccord Genuity Group increased their price objective on Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $76.29.

Remove Ads

Insider Buying and Selling

In other news, CEO Andrew Cheng sold 30,000 shares of the company's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $35.23, for a total transaction of $1,056,900.00. Following the completion of the sale, the chief executive officer now directly owns 624,324 shares in the company, valued at $21,994,934.52. This represents a 4.58 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Catriona Yale sold 10,000 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $49.87, for a total value of $498,700.00. Following the completion of the transaction, the insider now directly owns 95,648 shares in the company, valued at $4,769,965.76. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 341,309 shares of company stock valued at $15,863,578 and have sold 278,385 shares valued at $13,345,929. Corporate insiders own 7.94% of the company's stock.

Akero Therapeutics Trading Down 0.6 %

Shares of Akero Therapeutics stock traded down $0.22 during trading hours on Tuesday, reaching $37.38. 214,180 shares of the company's stock were exchanged, compared to its average volume of 855,620. The firm has a market capitalization of $2.98 billion, a price-to-earnings ratio of -9.97 and a beta of -0.18. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a 52-week low of $17.86 and a 52-week high of $58.40. The company has a fifty day moving average of $44.46 and a 200-day moving average of $35.98.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). Sell-side analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.